- Belgian Biotech company Bio-Sourcing has signed a partnership agreement with South African biotech
- This partnership will help develop a pilot program that will lead to BioMilk, a groundbreaking biotherapeutic platform
- This innovative technology aims to strengthen South Africa’s pharmaceutical sovereignty and drastically reduce production costs
South Africa – Bio-Sourcing, a Belgian biotech, has signed a partnership agreement with Afrigen Biologics, a South African biotech, to develop a pilot program in South Africa for a groundbreaking biotherapeutic platform, BioMilk.
BioMilk represents a significant leap forward in the development of novel therapies, aiming to address global unmet medical needs and improve access to biotherapeutics, such as monoclonal antibodies (mAbs) and insulin products.
The partners intend to create a new joint entity in South Africa to host the operations. Several public funding bodies have already expressed interest, and the venture is open to additional investors.
Join over 10k Partners and investors in Africa in our weekly emailing subscription list
Afrigen, which has previously pioneered the establishment of a state-of-the-art mRNA vaccine technology platform in Cape Town, and Bio-Sourcing, inventor of the technology underpinning BioMilk, believe that the platform will enable the end-to-end, including drug substance, manufacturing of the latest biologic medicines in South Africa.
Currently, biotherapeutic medicines such as mAbs are fully imported into South Africa at exorbitant prices, resulting in them being unavailable to the largest patient populations.
This innovative technology aims to strengthen South Africa’s pharmaceutical sovereignty and drastically reduce production costs, thus improving the affordability and accessibility of essential medicines in the fields of oncology and life-threatening autoimmune diseases.
“Our collaboration with Afrigen, a well-known and established player, represents an important step in the deployment of Bio-Sourcing in healthcare. I am thrilled to bring the BioMilk technology to Africa, where its benefits in terms of investment and production costs and sustainability are more critical than anywhere else. I look forward to the installation of our first bulk plant and to providing South Africa and other African countries with access to the medicines patients need,” said Bertrand Mérot, CEO of Bio-Sourcing.
Also read: Gambia Secures $16.8m Facility to Support Construction of Horizon Clinics
Gambia Secures $16.8m Facility to Support Construction of Horizon Clinics
Subscribe to our weekly newsletter and get industry reports and deals happening in Africa